GlassScriptPhysician profile
Noel R Williams
NPI 1215925110
$5,768.62
in general payments reported to CMS, 2019-2025
50 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,138 · 2020: $650 · 2021: $1,368 · 2022: $828 · 2023: $731 · 2024: $699 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,685 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,685.11 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $999.34 | 2019-2025 | Liletta |
| Astellas Pharma US INC | $658.47 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $550.52 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Gynesonics, INC. | $418.73 | 2021 | |
| Mayne Pharma Commercial LLC | $297.65 | 2021-2025 | |
| Daiichi Sankyo INC. | $251.41 | 2019-2023 | Injectafer |
| Amgen INC. | $214.06 | 2019-2021 | |
| Therapeuticsmd, INC. | $202.31 | 2019-2021 | |
| Minerva Surgical, INC | $170.21 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $147.72 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.92 | 2021-2024 | Xifaxan, Trulance |
| Medtronic USA, INC. | $129.71 | 2019-2020 | |
| Organon LLC | $127.74 | 2022-2025 | Nexplanon |
| Revance Therapeutics, INC. | $120.62 | 2024 | Daxxify |
| Corcept Therapeutics | $108.98 | 2019-2024 | Korlym |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $84.55 | 2023-2025 | Intrarosa, Femring, Femlyv |
| Bayer Healthcare Pharmaceuticals INC. | $83.47 | 2022-2024 | |
| Hologic Sales and Service, LLC | $75.65 | 2019-2024 | Aptima, Novasure, Coolseal Generator |
| Ascend Therapeutics US, LLC | $73.26 | 2019-2023 | |
| Avion Pharmaceuticals | $72.16 | 2021-2023 | Balcoltra |
| Axonics, INC. | $65.42 | 2024 | Axonics, Bulkamid |
| Allergan, INC. | $63.44 | 2019-2020 | |
| Pfizer INC. | $59.69 | 2019-2025 | |
| Horizon Therapeutics Plc | $50.86 | 2020-2023 | Tepezza |
| Lilly USA, LLC | $50.25 | 2020-2023 | Jardiance, Zepbound |
| Amag Pharmaceuticals, INC. | $43.69 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $39.85 | 2019-2022 | |
| Meditrina | $38.75 | 2022-2023 | |
| Supernus Pharmaceuticals, INC. | $33.48 | 2019-2022 | |
| Lupin INC. | $32.68 | 2019 | |
| Vertical Pharmaceuticals, LLC | $29.84 | 2019-2020 | |
| Eisai INC. | $29.64 | 2019-2020 | |
| Shire North American Group INC | $24.93 | 2019 | |
| Lundbeck LLC | $23.69 | 2022 | |
| Vivus LLC | $22.57 | 2019-2020 | |
| Ethicon US, LLC | $21.34 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.84 | 2019 | |
| Alfasigma USA, INC. | $19.24 | 2021 | |
| Roche Diagnostics Corporation | $18.39 | 2019 | |
| Sumitomo Pharma America, INC. | $18.03 | 2024 | Myfembree |
| Boston Scientific Corporation | $17.81 | 2025 | Axonics |
| Dexcom, INC. | $15.46 | 2024 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $15.30 | 2021 | |
| Agile Therapeutics, INC. | $14.79 | 2021 | |
| Coloplast Corp | $14.73 | 2021 | |
| Acella Pharmaceuticals, LLC | $14.64 | 2025 | NP Thyroid 60 |
| Bausch Health US, LLC | $13.88 | 2020 | |
| Antares Pharma, INC. | $11.87 | 2021 | |
| Janssen Biotech, INC. | $11.51 | 2019 | |
| Channel Medsystems, INC. | $5.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.